Entrata files for proposed IPO

Entrata (ENT) filed for a proposed IPO on the NYSE. Goldman Sachs, J.P. Morgan, and Barclays will serve as lead underwriters. The filing marks a step toward the company's public debut.

Original reporting
Published Sep 1, 2026, 10:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefIPO
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ENT
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

Low
01

Timing

today

Relevance 5/10Novelty 6/10Timing: today

Related articles

$ENTHigh

Why is Entain stock sliding today?

Entain (ENT) stock fell 2.7% after adjusting its 2026 financial guidance due to Brazil's ban on online sports betting. The company now expects lower-end EBITDA and online margin, with online net gaming revenue growth reduced to 4-6% from 5-7%. Brazil was projected to contribute 5% of revenue. The FTSE 100 rose 0.26% amid U.S.-Iran diplomacy news.

$ENTMedAI 8/10

Phased exit of Entain CEE - 20% divestment agreed

Entain said it agreed to sell a 20% interest in Entain Holdings (CEE) Ltd to joint venture partner EMMA Capital in a phased exit. The deal values Entain CEE at about €2.1bn (c.10x EBITDA) and provides ~€425m cash, including €395m on completion plus an early-2027 payment. Net proceeds will reduce debt; completion is expected in Q4 2026.

$ADRXHighAI 8/10

Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?

ADARx Pharmaceuticals aims to raise up to $371.9 million in a U.S. IPO, targeting a $1.74 billion valuation. The company plans to offer 21.9 million shares at $15-$17 each, listing on Nasdaq as ADRX. AbbVie Inc. (ABBV) will invest up to $100 million, gaining a 4.9% stake. ADARx has multiple drugs in development, with onvuzosiran in late-stage testing for hereditary angioedema. The IPO market remains selective, favoring companies with later-stage assets.

$CMedAI 8/10

Citigroup (C) Leads $3B+ IPO for Mexico's Grupo Financiero Banam

Citigroup (C) is leading a $3B+ IPO for Mexico's Grupo Financiero Banamex, set for January 2027, alongside Bank of America (BAC), Goldman Sachs (GS), and JPMorgan (JPM). Citigroup has sold stakes in Banamex before and is evaluating its remaining holdings. The company's stock is currently 46.2% overvalued at $134.28, with a dividend yield of 1.91% and a GF Score of 77/100.